The FDA is moving forward with plans to ease access to unproven peptide drugs popular among supporters of Health Secretary Robert F. Kennedy Jr. This proposal, which has been submitted for White House review, may allow the FDA to not enforce current restrictions on these drugs, despite warnings from FDA scientists about their unproven safety and efficacy. The Department of Health and Human Services has not commented on the matter.
Key facts
- FDA plans to ease access to unproven peptide drugs under Robert F. Kennedy Jr.
- FDA scientists have raised concerns about the safety and efficacy of these drugs.
- An "Interim Access Policy" on peptides has been submitted for White House review.
- The policy may grant the FDA enforcement discretion on certain peptide drugs.
- The Department of Health and Human Services did not respond to requests for comment.
A short AI summary in our own words. The reporting belongs to Ars Technica; we don't reproduce it.